--- title: "Anixa Biosciences (ANIX) news: offering" url: "https://aibio.space/companies/anixa-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANIX offering news: Anixa Biosciences files $200,000,000 replacement shelf with $100,000,000 ATM. Anixa Biosciences, Inc. (NASDAQ: ANIX), United States." --- ANIX Anixa Biosciences, Inc. NASDAQ · United States # Anixa Biosciences (ANIX) news ANIX offering news Financings · 2025-09-10 ## [Anixa Biosciences files $200,000,000 replacement shelf with $100,000,000 ATM](https://aibio.space/news/anixa-biosciences-files-200-000-000-replacement-shelf-100-000-000-atm/) Anixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials. ## Latest Anixa Biosciences news We have not published a story on Anixa Biosciences yet. When there is news, it will appear here. ## Anixa Biosciences at a glance - **Ticker**: ANIX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jul 31, 2026**: $13.9 million ### Related companies - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [Gilead Sciences](https://aibio.space/companies/gilead-sciences/) NASDAQ: GILD - [Editas Medicine](https://aibio.space/companies/editas-medicine/) NASDAQ: EDIT - [Allogene Therapeutics](https://aibio.space/companies/allogene-therapeutics/) NASDAQ: ALLO - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) NASDAQ: SMMT - [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX - [Novavax](https://aibio.space/companies/novavax/) NASDAQ: NVAX ### Also on NASDAQ - [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) LIMN - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) AGIO - [Tenon Medical](https://aibio.space/companies/tenon-medical/) TNON - [Oramed Pharmaceuticals](https://aibio.space/companies/oramed-pharmaceuticals/) ORMP - [Entrada Therapeutics](https://aibio.space/companies/entrada-therapeutics/) TRDA - [Tempus AI](https://aibio.space/companies/tempus-ai/) TEM ## What Anixa Biosciences does Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines for critical unmet needs in oncology. Its therapeutics program is liraltagene autoleucel (lira-cel), a chimeric endocrine receptor T cell therapy, a novel form of CAR-T technology initially focused on ovarian cancer. It is developed at its subsidiary Certainty Therapeutics, Inc., which holds an exclusive worldwide, royalty-bearing license to technology owned or controlled by The Wistar Institute. Lira-cel is in a Phase 1 trial with the H. Lee Moffitt Cancer Center and Research Institute, a dose-escalation study in recurrent epithelial ovarian cancer. Its vaccine programs include a breast cancer vaccine, developed under a license from The Cleveland Clinic Foundation and focused initially on triple-negative breast cancer, and an ovarian cancer vaccine. The breast cancer vaccine's Phase 1 trial reached final data, presented on December 11, 2025. A vaccine discovery program aims to develop additional cancer vaccines for lung, colon and prostate malignancies. | Product or program | What it is | Stage | |---|---|---| | Lira-cel (liraltagene autoleucel) | Chimeric endocrine receptor CAR-T therapy for ovarian cancer | Phase 1 | | Breast cancer vaccine | Vaccine against alpha-lactalbumin for triple-negative breast cancer | Phase 1, final data presented | | Ovarian cancer vaccine | Cancer vaccine for ovarian cancer | | Summarised from the company's [10-K filed Jan 12, 2026](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm). ## Anixa Biosciences annual financials | Line | FY ended Oct 31, 2025 | FY ended Oct 31, 2024 | |---|---|---| | Revenue | | [$210,000](https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/) | | Research and development | [$5.1 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | [$6.4 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | | Net income (loss) | [-$10.9 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | [-$12.6 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | | Cash from operations | [-$7.2 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | [-$7.3 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | | Cash and equivalents | [$1.2 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226041963/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | | Short-term investments | [$13.9 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226041963/) | [$18.7 million](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/) | Latest balance sheet, Jul 31, 2026 (10-Q): cash and equivalents $1.4 million, plus short-term investments of $12.5 million, $13.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Anixa Biosciences Has Anixa Biosciences raised money recently? Our latest story on this, dated Sep 10, 2025: "Anixa Biosciences files $200,000,000 replacement shelf with $100,000,000 ATM". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anixa-biosciences-files-200-000-000-replacement-shelf-100-000-000-atm/). What is the ticker symbol of Anixa Biosciences? Anixa Biosciences, Inc. trades under the ticker ANIX on NASDAQ. Where is Anixa Biosciences listed? Anixa Biosciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CY71; LSX:A2N6ZF. What is the SEC CIK of Anixa Biosciences? The SEC Central Index Key (CIK) for Anixa Biosciences, Inc. is 715446. Its filings are on SEC EDGAR. How many shares does Anixa Biosciences have outstanding? 34,763,802 shares as of 2026-09-09, per the cover page of its 10-Q filed 2026-09-09. Which country or territory is Anixa Biosciences listed under? Our directory records Anixa Biosciences, Inc. under United States. What does Anixa Biosciences do? Our directory classifies Anixa Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Anixa Biosciences? The ISIN recorded for Anixa Biosciences, Inc. is US03528H1095. Does aibio.space cover Anixa Biosciences? aibio.space lists Anixa Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Anixa Biosciences incorporated? SEC records list its state or country of incorporation as DE. What does Anixa Biosciences develop? Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines for critical unmet needs in oncology. Its therapeutics program is liraltagene autoleucel (lira-cel), a chimeric endocrine receptor T cell therapy, a novel form of CAR-T technology initially focused on ovarian cancer. What is Lira-cel (liraltagene autoleucel) from Anixa Biosciences? Lira-cel (liraltagene autoleucel): Chimeric endocrine receptor CAR-T therapy for ovarian cancer Stage: Phase 1. What is Breast cancer vaccine from Anixa Biosciences? Breast cancer vaccine: Vaccine against alpha-lactalbumin for triple-negative breast cancer Stage: Phase 1, final data presented. Is Anixa Biosciences profitable? Anixa Biosciences, Inc. reported a net loss of $10.9 million for the fiscal year ended Oct 31, 2025, and used $7.2 million of cash in operations, per its annual report to the SEC. How much does Anixa Biosciences spend on research and development? $5.1 million in the fiscal year ended Oct 31, 2025, per its annual report. ## Investor discussion: Anixa Biosciences Members talk about Anixa Biosciences (ANIX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Anixa Biosciences, newest first. Each line links the filing it comes from. 1. 2025-09-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/715446/000149315225013010/forms-3.htm) ## Press releases Headlines of Anixa Biosciences's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-26 PR Newswire [Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial](https://www.prnewswire.com/news-releases/anixa-biosciences-announces-completion-of-treatment-of-fifth-cohort-in-its-ovarian-cancer-car-t-clinical-trial-302918598.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ANIX on TradingView](https://www.tradingview.com/symbols/NASDAQ-ANIX/). ## SEC filings and registration - **SEC name**: Anixa Biosciences Inc - **CIK**: 715446 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANIX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: October 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118 - **Phone**: 408-708-9808 - **Shares outstanding**: 34,763,802 as of 2026-09-09 (10-Q filed 2026-09-09) - **Former names**: ITUS Corp; COPYTELE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/715446/000149315226041963/form10-q.htm) filed 2026-09-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/715446/000149315226028105/form10-q.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/715446/000149315226009699/form8-k.htm) filed 2026-03-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/715446/000149315226009370/form10-q.htm) filed 2026-03-09 - [8-K](https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/form8-k.htm) filed 2026-02-09 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/715446/000149315226004035/formdef14a.htm) filed 2026-01-28 - [10-K](https://www.sec.gov/Archives/edgar/data/715446/000149315226001845/form10-k.htm) filed 2026-01-12 - [8-K](https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/form8-k.htm) filed 2025-12-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000715446), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Anixa Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANIX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Anixa Biosciences, Inc. - **Ticker**: ANIX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US03528H1095 - **Other listed symbols**: GETTEX:CY71; LSX:A2N6ZF - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ANIX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/anixa-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anixa Biosciences (ANIX) news: offering", 2026-10-31, https://aibio.space/companies/anixa-biosciences/